Reviva Pharmaceuticals Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Reviva Pharmaceuticals Holdings generated cash of -$28,324,353, which is less than the previous year. Cash used in financing activities reached the amount of $33,171,953 last year. Net change in cash is therefore $4,847,600.
Cash Flow
| 2020 | -218.44K | 0 | 100K |
|---|---|---|---|
| 2020 | -3.72M | 0 | 12.82M |
| 2021 | -10.66M | 0 | 31.59M |
| 2023 | -28.32M | 0 | 33.17M |
RVPHW Cash Flow Statement (2019 – 2023)
| 2023 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
Cash at beginning of period | 18.51M | 8.76M | 193 | 118.63K |
Operating activities | ||||
Net income | -39.26M | -8.52M | -3.78M | -846.83K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 0 | 0 | 591 | 645 |
Stock-based compensation expense | 3.41M | 106.71K | 0 | 0 |
| Deferred income tax benefit | 3.41M | 106.71K | 0 | 0 |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 |
Accounts payable | 328.83K | -498.46K | 775.10K | 158.17K |
Cash generated by operating activities | -28.32M | -10.66M | -3.72M | -218.44K |
Investing activities | ||||
Purchases Of Investments | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 |
Financing activities | ||||
Common Stock Issued | 27.49M | 31.49M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 |
Cash used in financing activities | 33.17M | 31.59M | 12.82M | 100K |
Net Change In Cash | 4.84M | 20.92M | 8.76M | -118.44K |
Cash at end of period | 23.36M | 29.68M | 8.76M | 193 |
| Data source | Data source | Data source | Data source |